|
Title
|
|
|
|
Novel Alzheimer risk genes determine the microglia response to amyloid-β but not to TAU pathology
| |
|
Author
|
|
|
|
| |
|
Abstract
|
|
|
|
| Polygenic risk scores have identified that genetic variants without genome-wide significance still add to the genetic risk of developing Alzheimer's disease (AD). Whether and how subthreshold risk loci translate into relevant disease pathways is unknown. We investigate here the involvement of AD risk variants in the transcriptional responses of two mouse models: APPswe/PS1(L166P) and Thy-TAU22. A unique gene expression module, highly enriched for AD risk genes, is specifically responsive to A beta but not TAU pathology. We identify in this module 7 established AD risk genes (APOE, CLU, INPP5D, CD33, PLCG2, SPI1, and FCER1G) and 11 AD GWAS genes below the genome-wide significance threshold (GPC2, TREML2, SYK, GRN, SLC2A5, SAMSN1, PYDC1, HEXB, RRBP1, LYN, and BLNK), that become significantly upregulated when exposed to A beta. Single microglia sequencing confirms that A beta, not TAU, pathology induces marked transcriptional changes in microglia, including increased proportions of activated microglia. We conclude that genetic risk of AD functionally translates into different microglia pathway responses to A beta pathology, placing AD genetic risk downstream of the amyloid pathway but upstream of TAU pathology. |
| |
|
Language
|
|
|
|
English
| |
|
Source (journal)
|
|
|
|
EMBO molecular medicine. - -
| |
|
Publication
|
|
|
|
2020
| |
|
ISSN
|
|
|
|
1757-4676
1757-4684
| |
|
Volume/pages
|
|
|
|
12
:3
(2020)
, 18 p.
| |
|
Article Reference
|
|
|
|
e10606
| |
|
ISI
|
|
|
|
000519251300003
| |
|
Pubmed ID
|
|
|
|
31951107
| |
|
Medium
|
|
|
|
E-only publicatie
| |
|
Full text (open access)
|
|
|
|
| |
|